Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR known ✓ | P02766 | 1/20 | 0.37 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.37 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.37 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.37 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | ACACA | Q13085 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.40 |
| ▸ | PPARA | Q07869 | 8/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL561986 | 1.00 | ACLY (0.50) | ACLYACACBACACATBXAS1PPARA | |
| SCHEMBL232205 | 0.98 | ACLY (0.52) | ACLYACACBACACATBXAS1PPARA | |
| Hydrochloric Acid SCHEMBL621977 | 0.93 | ACLY (0.53) | ACLYACACBACACATBXAS1PPARA | |
| Hydrochloric Acid SCHEMBL562371 | 0.93 | ACLY (0.53) | ACLYACACBACACATBXAS1PPARA | |
| Hydrochloric Acid SCHEMBL561963 | 0.91 | ACLY (0.57) | ACLYACACBACACATBXAS1PPARA | |
| Hydrochloric Acid SCHEMBL1175992 | 0.91 | ACLY (0.57) | ACLYACACBACACATBXAS1PPARA | |
| SCHEMBL154712 | 0.91 | ACLY (0.55) | ACLYACACBACACATBXAS1PPARA | |
| SCHEMBL250911 | 0.89 | ACLY (0.59) | ACLYACACBACACATBXAS1PPARA | |
| Hydrochloric Acid SCHEMBL561987 | 0.86 | KDM4E (0.35) | ACLYACACBACACACYP1A2CYP2C9 | |
| SCHEMBL1106837 | 0.86 | ACLY (0.43) | ACLYACACBACACATBXAS1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010063725-A2 | STRUCTURING PARTICLES INTO USEFUL STRUCTURES AND THEIR USE IN LIFE SCIENCE | MATTIASSON BO (SE) | 2010-06-10 | — | — | WO | claimed |
| US-7538092-B2 | Pharmaceutically active oligosaccharide conjugates | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2009-05-26 | — | — | US | claimed |
| EP-1549350-B1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | FRESENIUS KABI DE GMBH (DE) | 2008-09-24 | — | — | EP | claimed |
| US-20080090918-A1 | Separation medium, its preparation and its use | PROTISTA BIOTECHNOLOGY AB (SE) | 2008-04-17 | — | — | US | claimed |
| US-20060100163-A1 | Pharmaceutically active oligosaccharide conjugates | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2006-05-11 | — | — | US | claimed |
| US-20050029191-A1 | Macroporous gel; cooling aqueous solution of gel forming polymer and solvent at a temperature which freezes solvent | PROTISTA BIOTECHNOLOGY AB (SE) | 2005-02-10 | — | — | US | claimed |
| EP-1436058-A1 | SEPARATION MEDIUM, ITS PREPARATION AND ITS USE | Protista International AB (SE) | 2004-07-14 | — | — | EP | claimed |
| US-20030148304-A1 | Method for immobilisation | KAROLINSKA INNOVATIONS AB (SE) | 2003-08-07 | — | — | US | claimed |
| WO-2003031014-A1 | SEPARATION MEDIUM, ITS PREPARATION AND ITS USE | PROTISTA INTERNATIONAL AB (SE) | 2003-04-17 | — | — | WO | claimed |
| EP-1235937-A1 | METHOD FOR IMMOBILISATION | Karolinska Innovations AB (SE) | 2002-09-04 | — | — | EP | claimed |
| WO-2001042501-A1 | METHOD FOR IMMOBILISATION | KAROLINSKA INNOVATIONS AB (SE) | 2001-06-14 | — | — | WO | claimed |
| EP-0248621-B1 | REAGENT FOR IMMUNOASSAY | KABUSHIKI KAISHA TOSHIBA (JP) | 1992-08-26 | — | — | EP | claimed |
| US-8765115-B2 | Method of treatment of gastrointestinal disorders with IL-10 | National Institute of Agrobiological Scienses (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20120328561-A1 | METHOD FOR TREATMENT OF INFLAMMATORY GASTROINTESTINAL DISORDERS | NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES (JP) | 2012-12-27 | — | — | US | disclosed |
| WO-2010063725-A2 | STRUCTURING PARTICLES INTO USEFUL STRUCTURES AND THEIR USE IN LIFE SCIENCE | MATTIASSON BO (SE) | 2010-06-10 | — | — | WO | disclosed |
| CN-101223169-A | Pyrrolo [2, 3-b ] pyridine derivative protein kinase inhibitors | PLEXXIKON INC (US) | 2008-07-16 | — | — | CN | disclosed |
| US-4318982-A | FMN-Labeled specific binding assay | MILES LABORATORIES, INC. (US) | 1982-03-09 | — | — | US | disclosed |
| US-4279992-A | Specific binding assay employing an enzyme-cleavable substrate as label | MILES LABORATORIES, INC. (US) | 1981-07-21 | — | — | US | disclosed |
| US-4255566-A | N6-(OMEGA-AMINOALKYL)ADENINE DINUCLEOTIDE DERIVATIVES; IMMUNOASSAY | MILES LABORATORIES (US) | 1981-03-10 | — | — | US | disclosed |
| US-4238565-A | Specific binding assay with a prosthetic group as a label component | MILES LABORATORIES, INC. (US) | 1980-12-09 | — | — | US | disclosed |